IFNA1 and COVID-19: IFN-I is therefore an emerging candidate for COVID-19 treatment, as IFN-α and IFN-ß are also able to inhibit SARS-CoV-2 replication (Hensley et al., 2004; Clementi et al., 2020; Felgenhauer et al., 2020).